MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

Protocol Title

M13-694 VELIA A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel with or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subject with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M19-037 A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumours

M19-345 A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumours

MDNA11-01 ABILITY A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumours

MDV3100-10 PLATO A Phase 4, Randomized, Double Blind, Placebo Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients with Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer

MDV3100-13 EMBARK A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide plus Leuprolide, Enzalutamide Monotherapy, and Placebo plus Leuprolide in Men with High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

MDV3100-13 EMBARK A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide plus Leuprolide, Enzalutamide Monotherapy, and Placebo plus Leuprolide in Men with High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy

MDV3100-14 PROSPER A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

MDV3100-14 PROSPER Prosper: a Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safet Study of Enzalutamide in Patients with Non-metastatic CastrationResistant Prostate Cancer

MDV3100-14 PROSPER A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer